CalciMedica Inc. (NASDAQ:CALC) Stock Has Average Target Price of $50.00 According to Analysts

CalciMedica Inc. (NASDAQ:CALC) has been assigned an average recommendation of “Hold” from the five research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $50.00.

Several equities research analysts have recently commented on the company. Weiss Ratings upgraded CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Guggenheim initiated coverage on CalciMedica in a research note on Thursday, August 20th. They set a “buy” rating for the company. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Finally, Wall Street Zen lowered CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th.

Hedge Funds Weigh In On CalciMedica

A hedge fund recently raised its position in CalciMedica stock. Renaissance Technologies LLC grew its holdings in CalciMedica Inc. (NASDAQ:CALC) by 45.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 128,075 shares of the company’s stock after acquiring an additional 39,775 shares during the period. Renaissance Technologies LLC owned about 0.81% of CalciMedica worth $69,000 as of its most recent filing with the Securities & Exchange Commission.

CalciMedica Stock Up 4.6%

Shares of NASDAQ CALC opened at $1.36 on Tuesday. The company has a market cap of $9.29 million, a price-to-earnings ratio of -0.20 and a beta of 0.84. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 1.67. The stock has a 50-day moving average price of $1.62 and a two-hundred day moving average price of $3.63. CalciMedica has a 12 month low of $1.00 and a 12 month high of $36.00.

CalciMedica (NASDAQ:CALC) last posted its earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.97. As a group, analysts forecast that CalciMedica will post -5.25 earnings per share for the current fiscal year.

CalciMedica Company Profile

CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.